Related Experiment Video
Updated: Dec 29, 2025
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
RUNX1 Dosage in Development and Cancer.
Michael Lie-A-Ling1,2, Renaud Mevel1,2, Rahima Patel1
1Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, SK10 4TG, UK.
RUNX1 gene dosage impacts acute myeloid leukemia (AML) and normal blood cell development. Altered RUNX1 levels also serve as cancer progression markers in various tissues.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- The transcription factor RUNX1 is crucial for hematopoietic system development.
- RUNX1 gained prominence due to its role in acute myeloid leukemia (AML) via the t(8;21) translocation.
- RUNX1's function extends beyond leukemia to normal hematopoiesis and other cancers.
Purpose of the Study:
- To review the current understanding of RUNX1 dosage effects.
- To explore RUNX1's role in normal hematopoietic and epithelial tissue development.
- To discuss RUNX1's significance in associated cancers.
Main Methods:
- Literature review of studies on RUNX1.
- Analysis of RUNX1's function in normal development.
- Examination of RUNX1's role in hematopoietic and non-hematopoietic cancers.
Main Results:
- RUNX1 dosage critically influences both leukemia and normal hematopoietic development.
- RUNX1 expression levels can indicate tumor progression in hematopoietic and non-hematopoietic cancers.
- RUNX1 plays a role in the ontogeny of the normal hematopoietic system.
Conclusions:
- RUNX1 dosage is a key factor in hematopoietic development and leukemia.
- RUNX1 expression levels are valuable biomarkers for cancer progression.
- Understanding RUNX1 dosage is essential for both normal development and cancer research.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021